论文部分内容阅读
目的：探讨中药辨证治疗配合同步放、化疗对晚期非小细胞肺癌（NSCLC）的影响。方法：对56例（A组）晚期NSCLC患者采用中医辨证治疗加同步放、化疗，并与44例同步放、化疗（B组）及34例放、化疗（C组）进行对照，结果：A、B、C组近期有效率分别为87．5％、84．1％、55．9％，A、B两组优于C组（P＜0．01）；中位生存期A组为16．4个月，B组为11．8个月，C组为10．6个月；2、3年生存率A组明显高于B组（P＜0．05），且A组患者临床症状变化、卡氏评分、免疫功能明显改善（P＜0．05，P＜0．01）。结论：中药配合同步放、化疗对晚期NSCLC患者的免疫功能，生存质量，延长生存时间均优于单纯同步放、化疗及放、化疗。
OBJECTIVE: To investigate the effect of traditional Chinese medicine differentiation therapy combined with concurrent radiotherapy and chemotherapy on advanced non-small cell lung cancer (NSCLC). METHODS: 56 patients (group A) with advanced NSCLC were treated with TCM syndrome differentiation therapy plus concurrent radiotherapy and chemotherapy, and compared with 44 patients with concurrent radiotherapy and chemotherapy (group B) and 34 patients with radiotherapy and chemotherapy (group C). Result: A The effective rates in the group B, C were 87.5%, 84.1%, and 55.9%, respectively. The A and B groups were superior to the C group (P<0.01); the median survival period was 16 in the group A. .4 months, 11.8 months in group B and 10.6 months in group C; 2 and 3 years survival rates were significantly higher in group A than in group B (P<0.05), and clinical symptoms in group A The change, Karnofsky score, and immune function were significantly improved (P<0.05, P<0.01). CONCLUSION: Chinese medicine combined with concurrent radiotherapy and chemotherapy has better effects on immune function, quality of life, and prolongation of survival in patients with advanced NSCLC than that of concurrent chemotherapy, radiotherapy and chemotherapy.